Related Experiment Videos
Pharmacokinetics of carbamazepine in the neonate and in the child
Insights
Carbamazepine
Area of Science:
- Pharmacokinetics
- Pediatric Pharmacology
- Epilepsy Treatment
Background:
- Carbamazepine is a widely used antiepileptic drug.
- Limited pharmacokinetic data exists for carbamazepine in newborns and children.
- Understanding drug metabolism in pediatric populations is crucial for effective treatment.
Purpose of the Study:
- To investigate the pharmacokinetics of carbamazepine in pediatric epilepsy patients.
- To determine key pharmacokinetic parameters such as absorption and elimination half-lives.
- To compare pediatric pharmacokinetic data with existing adult data.
Main Methods:
- Studied 7 newborns and 5 children with epilepsy receiving oral carbamazepine.
- Measured serum carbamazepine concentrations using gas-liquid chromatography.
- Applied a one-compartment body model to calculate pharmacokinetic constants.
Main Results:
- Carbamazepine absorption was delayed, with peak concentrations occurring 2-9 hours post-administration.
- Mean absorption half-life was 1.42 ± 0.34 hr; mean elimination half-life was 8.76 ± 0.85 hr.
- Elimination half-life was significantly shorter than reported in adult patients.
Conclusions:
- Pediatric carbamazepine pharmacokinetics differ from adults, with faster elimination.
- Predicted steady-state concentrations based on initial parameters did not match measured values in chronic treatment simulations.
- Further research is needed to optimize carbamazepine dosing in children.
Abstract:
1. Pharmacokinetic of carbamazepine were made in 7 new-borns and in 5 children. They were hospitalized for epilepsy and were receiving drugs such as phenobarbital alone or in association with other antiepileptic drugs, but not with carbamazepine. 2. The drug was given by oral route with a mean dose of 17.2 mg.kg-1. 3. The determination of carbamazepine concentration in serum was made by gas liquid chromatography on a 50 microliter sample. 4. A one compartment body model was used to determine the pharmacokinetic constants with first order rate constants for absorption and elimination. 5. Absorption was generally delayed by about half an hour, the maximum concentrations ranging from 3.14 to 10 microgram.ml-1 at 2 and 9 hr after administration. The mean half-life for absorption was 1.42 +/- 0.34 hr. The mean half-life for elimination was 8.76 +/- 0.85 hr. The half-life for elimination was much shorter than those already described even in multiple dosing epileptic adult patients. The pharmacokinetic parameters were used to predict blood levels in chronic treatment in 3 children. The predicted steady state concentrations disagreed with the concentrations measured.